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Abstract
Background: Rasmussen’s encephalitis (RE) is an inflammatory encephalopathy of unknown cause defined by
seizures with progressive neurological disabilities. Herein, the pathogenesis of RE was investigated focusing on
inflammasome activation in the brain.
Methods: Patients with RE at the University of Alberta, Edmonton, AB, Canada, were identified and analyzed by
neuroimaging, neuropsychological, molecular, and pathological tools. Primary human microglia, astrocytes, and
neurons were examined using RT-PCR, enzyme-linked immunosorbent assay (ELISA), and western blotting.
Results: Four patients with RE were identified at the University of Alberta. Magnetic resonance imaging (MRI)
disclosed increased signal intensities in cerebral white matter adjacent to cortical lesions of RE patients,
accompanied by a decline in neurocognitive processing speed (P <0.05). CD3ε, HLA-DRA, and TNFα together with
several inflammasome-associated genes (IL-1β, IL-18, NLRP1, NLRP3, and CASP1) showed increased transcript levels in
RE brains compared to non-RE controls (n = 6; P <0.05). Cultured human microglia displayed expression of
inflammasome-associated genes and responded to inflammasome activators by releasing IL-1β, which was inhibited
by the caspase inhibitor, zVAD-fmk. Major histocompatibility complex (MHC) class II, IL-1β, caspase-1, and alanine/
serine/cysteine (ASC) immunoreactivity were increased in RE brain tissues, especially in white matter myeloid cells,
in conjunction with mononuclear cell infiltration and gliosis. Neuroinflammation in RE brains was present in both
white matter and adjacent cortex with associated induction of inflammasome components, which was correlated
with neuroimaging and neuropsychological deficits.
Conclusion: Inflammasome activation likely contributes to the disease process underlying RE and offers a
mechanistic target for future therapeutic interventions.
Keywords: Rasmussen’s encephalitis, White matter, Inflammasome, Innate immunity
Background
Rasmussen’s encephalitis (RE) is a rare progressive enceph-
alopathy defined by chronic focal epilepsy, neurocognitive,
and motor deficits with neuroinflammation [1,2]. Clinical
features of RE include intractable seizures, hemiparesis,
blindness, and neurocognitive dysfunction [3]. The major
seizure semiology associated with RE is epilepsia partialis
continua, which is difficult to control with current anti-
epileptic drugs [4]. RE is chiefly a disease of children but
occasionally occurs in adulthood (10%) and can be fatal de-
pending on the severity of the disease. Treatment options
for RE are limited to controlling the seizures with anti-
epileptic drugs together with radical neurosurgical interven-
tions (corticectomy or hemispherectomy) associated with
major postoperative neurologic deficits including hemipar-
esis and hemianopsia [5]. Therapeutic immunomodulation
and/or immunoablation in RE as well as antiviral therapies
have been reported with inconclusive results [6,7].
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Although there is substantial clinical heterogeneity, RE
usually displays neuropathological features consisting of
inflammation, gliosis, and tissue destruction in the cortex
of the affected hemisphere, often with relative sparing of
the basal ganglia, contralateral hemisphere, and posterior
fossa structures. The observed inflammatory changes in
RE include perivascular cuffing, microglial nodules, T
lymphocytic infiltration gliosis, meningeal inflammation,
and neuronal injury or loss [2,8]. The underlying etiology
of RE is unknown; several exogenous pathogens have been
postulated as causative [9] but autoimmune mechanisms
have also been reported, largely based on the infiltration
of T lymphocytes (CD8+) and macrophages at the disease
onset accompanied by gliosis and neurodegeneration in
the cerebral cortex [10].
Inflammation in the nervous system occurs in multiple
neurological disorders with diverse causes and pathological
phenotypes. Recently, the contribution of innate immunity
to neurological disease has garnered increased attention,
especially with the recognition of inflammasome activation
[11]. Inflammasomes represent complex protein aggregates
formed by cytosolic receptors, their adaptor proteins, and
caspase-1, which regulate the maturation and release of IL-
1β and IL-18 [12]. Activation of an inflammasome involves
an orchestrated engagement of cell signaling molecules
that primes cells to express pro-IL-1β (signal 1) with
subsequent signals that trigger the formation of an
inflammasome complex (signal 2). The formation of
these complexes mediates the cleavage and release of
active IL-1β, which participates in the development
and promulgation of inflammatory responses. Inflam-
masome activation has recently been implicated in
bacterial meningitis, autoimmune demyelination, and
chronic neurodegenerative disease [13-15]. Nonetheless,
little is known about inflammasome expression and func-
tion in human neural cells.
Given the disabling nature of the motor features associ-
ated with RE together with previous imaging and neuro-
pathological studies suggesting white matter involvement,
we hypothesized that the disease process extended beyond
the cortex into the proximal white matter in RE and might
engage inflammasome cellular components because of RE’s
inflammatory features. In fact, the present studies revealed
that among RE patients there was converging evidence of
white matter pathogenesis, based on neuropsychological,
neuroimaging, molecular, and neuropathological analyses.
Moreover, induction of multiple components implicated in
inflammasome expression was evident in both cortex and




A retrospective review of all patients diagnosed with RE
in the Comprehensive Epilepsy Program was performed
based on the published criteria for RE [4], using the
demographic, clinical, laboratory, neuroimaging, and
treatment data of patients followed in this program, with
University of Alberta (Edmonton, AB, Canada) Ethics
Committee approval. To confirm, corroborate, and es-
tablish the diagnosis of RE, all patients referred to the
program with epilepsy and an abnormal cranial magnetic
resonance imaging (MRI) were evaluated by a pediatric
epileptologist (DBS, RTW). The patients presented
herein (n = 4; ages 3 to 14 years) represent all identified
cases of RE during the years from 1999 to 2009
(Table 1). Patient control brain specimens (mean age
19.4 ± 12.9 years; males, n = 4; mesial temporal sclerosis
Table 1 Clinical features of RE patients
Patient 1 Patient 2 Patient 3 Patient 4
Age of onset, gender 3 years, female 8 years, female 14 years, male 12 years, female
Seizure type CPS, Gen, right
face/hand EPC
CPS, right face/hand EPC CPS, right face/hand EPC CPS, right
face/hand EPC
Hemisphere Left Left Bilateral Left
Neurologic deficit(s) Right hemiparesis Right hemiparesis Right hemiparesis, aphasia Right hemiparesis
Neuroimaging Cortical and white matter
signal
Cortical and white matter
signal
Cortical and white matter signal Cortical and white
matter signal
















Clinical outcome Engel class I, seizure-free
(at 14 months)
Engel class I, seizure-free
(at 24 months)
Engel class IV, death Engel class III, 2 years
(lost to follow-up)




CPS, complex partial seizure; EPC, epilepsia partialis continua; GCs, glucocorticoids; Gen, generalized seizures; IVIg, intravenous immune globulin; RE, Rasmussen’s
encephalitis; SPT, subpial transaction.
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(n = 5), multiple sclerosis (n = 1)) for the molecular studies
included both cortex and white matter.
Neuropsychological studies
Neuropsychological assessments were conducted for clin-
ical purposes of treatment and educational planning. The
frequency of assessments varied among patients (patients 2,
3, and 4) depending on their clinical course, response to
therapies, and medical interventions. However, for all cases
the test battery included standard measures of intelligence
(Wechsler Intelligence Scale for Children (WISC):
WISC-III or WISC-IV), language (Boston Naming Test
(BNT), Controlled Oral Word Association (COWA),
animal naming), immediate and delayed verbal and visual
memory (Wide Range Assessment Memory and Learning
(WRAML) Story Memory and Design Memory, Rey Audi-
tory Verbal Learning Test (AVLT), Rey-Osterrieth Com-
plex Figure (ROCF)), motor skills (finger tapping, grooved
pegboard), and processing speed (WISC coding/index,
Trail Making Test (TMT) Part A). Serial neuropsycho-
logical examinations were performed at presentation and
at subsequent time points (1 year after initial assessment
for patients 2 and 4; 2 years after initial assessment for pa-
tient 3) as part of routine evaluation prior to surgery [16].
Tissue samples
Frozen brain tissue (cortex and white matter) was col-
lected from RE patients (n = 3, tissue was not available
from patient 4) and control subjects undergoing cerebral
resections for epilepsy (non-RE; n = 5; mean age 19 ±
10 years) for molecular and neuropathological studies,
as described previously [17]. These studies were ap-
proved by the University of Alberta Ethics Committee
(Pro00002291).
Neuropathological studies
All patients underwent hemispherectomy or cortical re-
section and all tissues were reviewed at gross assessment
and after histological and immunocytochemical staining
by a certified neuropathologist (EJ) [17]. Next, 10 μM
paraffin-embedded sections of human brain tissue from
RE and non-RE were deparaffinized and hydrated using
decreasing concentrations of ethanol. Sections were
boiled in 0.01 M citrate buffer, pH 6.0, for 10 minutes
prior to application of antibodies that detected CD3,
CD8, CD68, vimentin, IL-1β, caspase-1, major histocom-
patibility complex (MHC) class II, and alanine/serine/
cysteine (ASC); antibodies included anti-ASC (AL177,
Adipogen, San Diego, CA, USA), anti-IL-1β and anti-
caspase-1 (sc-7884 and sc-515, respectively, Santa Cruz
Biotechnology, Dallas, TX, USA), anti-MHC class II
(M0775, Dako, Glostrup, Denmark), anti-IL18 (D043-3,
MBL International, Woburn, MA, USA), anti-CD3 (790–
4341, Ventana, Tuscon, AZ, USA), anti-CD8 (M7103,
Dako), anti-CD68 (M0814, Dako), and anti-vimentin
(M0725, Dako). Primary antibodies were diluted in PBS/
serum and incubated overnight at room temperature.
Immunolabeling with primary antibodies was detected
with biotinylated goat-anti-rabbit or biotinylated goat-
anti-mouse (Vector Laboratories, Burlingame, CA,
USA) and avidin-biotin-peroxidase complex (ABC,
Vector Laboratories). Sections were counter-stained
with hematoxylin.
Human neural cell cultures
Human fetal astrocytes (HFAs), microglia, and neurons
were prepared from 15- to 19-week fetal brains obtained,
with consent (approved by the University of Alberta Eth-
ics Committee, Pro00027660), as previously described
[17-21]. Briefly, fetal brain tissues were dissected, menin-
ges were removed and digested for 30 minutes with 2.5%
trypsin (Life Technologies, Burlington, ON, Canada) and
2 mg/mL DNase I (Roche Diagnostics, Mannheim,
Germany), and passaged through a 70 μm cell strainer
(BD Biosciences, Mississauga, ON, Canada). Cells were
washed twice with centrifugation at 14,000 rpm for 10 mi-
nutes and plated in T-75 flasks coated with poly-
L-ornithine (Sigma-Aldrich, Oakville, ON, Canada) at 6 to
8 × 107 cells/flask with media. Following a week of incu-
bation (37°C at 5% CO2), adherent HFAs were separated
from suspended microglia and re-plated for primary astro-
cytic, neuronal, or microglia differentiation (80% conflu-
ence). Cells were maintained in MEM containing 10% FBS
(Life Technologies), 1% penicillin/streptomycin (Life Tech-
nologies), 1% L-glutamine (Life Technologies), and 10%
dextrose (Life Technologies).
Real-time RT-PCR
Tissues were homogenized and then lysed in TRIzol
(Invitrogen, Carlsbad, CA, USA) and used in real-time
PCR analyses as previously described. Briefly, human
cerebral samples (white matter and adjacent cortex) and
cultured cells were homogenized in TRIzol and total
RNA was purified from the aqueous phase using RNeasy
mini columns (Qiagen, Valencia, CA, USA) [16]. Follow-
ing digestion of RNA with DNase I (Promega, Madison,
WI, USA), cDNA was prepared by oligo(dT) primed re-
verse transcription of equal quantities of RNA using
either SuperScript II or SuperScript III Reverse Tran-
scriptase (Invitrogen) according to the manufacturer’s
recommended protocols. Semi-quantitative real-time
RT-PCR was performed using iQ SYBR Green super-
mix (Bio-Rad Laboratories, Hercules, CA, USA) on either
an iQ5 or iCycler (Bio-Rad Laboratories) according
to the manufacturer’s recommended protocols. Oligo-
nucleotide PCR primers are provided in Table 2. All
data were normalized to GAPDH mRNA levels and
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expressed as relative fold changes (RFCs) compared to
non-RE controls.
In vitro activation and protein expression
To stimulate protein expression or release from primary
microglia or astrocytes, cells isolated as described above
were seeded at a density of 7 × 105 cells/well and
treated for 18 hours with either TNFα (50 ng/mL) or
LPS (25 ng/mL). Following LPS priming, cells were
treated for 2 hours with either ATP (500 μM) or
MDP (500 ng/mL) for 6 hours to further trigger forma-
tion of inflammasome complexes. The caspase inhibi-
tor, zVAD-fmk (100 μM), was used to inhibit these
responses. Cell lysates from treated cells were collected
in standard Laemmli sample loading buffer run on 12%
gels and analyzed by western blot. The same antibodies
used for immunohistochemistry were used for western
blotting (see above). Alternatively, to measure release of
IL-1β from stimulated cells, cell culture supernatants
were collected and analyzed by enzyme-linked im-
munosorbent assay (ELISA; DY201, R&D Systems,
Minneapolis, MN, USA).
Statistical analyses
For determination of differences in neuropsychological
performance and transcript levels, Mann–Whitney U or
Student’s t-tests were performed using GraphPad Prism
version 5 for OS X (GraphPad Software, San Diego, CA
USA; www.graphpad.com). P values <0.05 were consi-
dered significant.
Results
Clinical and demographic features
Herein, four individuals were identified with clinical, im-
aging, and pathological features of RE, ranging in age from
3 to 14 years at the time of presentation (three females,
one male), exhibiting different seizure types and outcomes
(Table 1), and all of whom underwent surgery for removal
of the epileptogenic regions. All patients exhibited neuro-
pathological features characteristic of RE including astro-
gliosis, leukocyte infiltration, and neuronal injury.
Neuroimaging and neuropsychological studies
Serial cranial MRI demonstrated increased signal apparent
in both the cortex and adjacent matter in the affected
(left) hemisphere (T2-weighted) for patient 2 (Figure 1A)
with minimal gadolinium enhancement (data not shown).
Similarly, patient 3 also exhibited increased signal in both
cortex and white matter, which progressed over time and
remained apparent after a partial resection of the lesion.
Patients 1 and 4 demonstrated normal neuroimaging at
presentation but developed significant atrophy of cortex
and white matter of the left hemisphere within months
of presentation (data not shown). Among patients 2, 3,
and 4, longitudinal neuropsychological analyses were
performed prior to surgery using established tests of
language, attention, memory, motor functions, and pro-
cessing speed. Median T scores (n = 3, patients 2 to 4)
declined significantly between first and last assessments
for processing speed, while memory (verbal and non-
verbal), language, dominant motor, and non-dominant
motor performances remained unchanged over time
(Figure 1B). As expected with left hemispheric lesions,
language function was reduced in all three patients at
both early and late time points. Reliable neuropsycho-
logical assessment could not be performed in patient 1
due to the early age at presentation. The reduction in
processing speed efficiency herein implied that subcor-
tical structures might be affected, prompting examin-
ation of both cortex and adjacent white matter with
molecular and morphological tools.
Host neuroimmune responses
Earlier studies indicate that leukocyte infiltration was a key
aspect of the neuropathogenesis of RE [22,23], perhaps in
response to expression of host autoantigens or infectious
agents. Comparison of cortex and white matter transcript
Table 2 Oligonucleotide PCR primers
Gene Primer
ASC Forward 5′-GCC TGC ACT TTA TAG ACC AGC-3′
Reverse 5′-GCT TCC GCA TCT TGC TTG G-3′
CASP1 Forward 5′-TCC AAT AAT GGA CAA GTC AAG CC-3′
Reverse 5′-GCT GTA CCC CAG ATT TTG TAG CA-3′
CD3e Forward 5′-GAT GCA GGG CAC TCA CT-3′
Reverse 5′-CAT TAC CAT CTT GCC CCC AA-3′
GAPDH Forward 5′-AGC CTT CTC CAT GGT GGT GAA GAC-3′
Reverse 5′-CGG AGT CAA CGG ATT TGG TCG-3′
HLA-DRA Forward 5′-GGA CAA AGC CAA CCT GGA AA-3′
Reverse 5′-AGG ACG TTG GGC TCT CTC AG-3′
IL1b Forward 5′-CCA AAG AAGAAG ATG GAA AAG C-3′
Reverse 5′-GGT GCT GAT GTA CCA GTT GGG-3′
IL18 Forward 5′-TCT TCA TTG ACC AAG GAA ATC GG-3′
Reverse 5′-TCC GGG GTG CAT TAT CTC TAC-3′
NLRP1 Forward 5′-ATT CCA GTT TGT GCG AAT CCA-3′
Reverse 5′-GTT CCT TGG GGA GTA TTT CCA G-3′
NLRP3 Forward 5′-GAT CTT CGC TGC GAT CAA CAG-3′
Reverse 5′-CGT GCA TTA TCT GAA CCC CAC-3′
NLRC4 Forward 5′-TGC ATC ATT GAA GGG GAA TCT G-3′
Reverse 5′-GAT TGT GCC AGG TAT ATC CAG G-3′
CD8 Forward 5′-CCG ACG ATC ATG CAG AAG TA-3′
Reverse 5′-GGT GAA GAG GTG GAA CAG GA-3′
GFAP Forward 5′-GAG ATC GCCACC TAC AG-3′
Reverse 5′-CAC ATC CTT GRG CTC CTG-3′
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levels revealed that HLA-DR and CD3ε transcript levels
were significantly increased in both cortex and adjacent
white matter of RE patients (patients 1, 2, 3) compared
to matched regions from non-RE patients (Figure 2A;
Additional file 1). In addition, TNF-α transcript levels
were induced in the white matter of RE patients compared
to non-RE patients as well as matched cortical samples,
while GFAP transcript levels were non-significantly in-
creased in the white matter of RE patients (Figure 2A).
Given the extent of neuroinflammation in the brain speci-
mens of RE patients, particularly in white matter, the
molecular machinery involved in inflammasome activation
was investigated revealing that IL-1β transcript levels were
increased in the white matter of RE patients compared
to white matter from non-RE patients and matched RE
cortical specimens (Figure 2B). Further analyses disclosed
that NLRP1 and NLRP3 transcript levels were increased in
RE white matter and cortex, while casp1 and IL-18 tran-
script levels were also significantly increased in both white
matter and cortex of RE patients. ASC mRNA expression
was selectively increased (by >80 fold) in white matter of
RE patients (Figure 2B). These observations pointed to
substantial increases in expression of genes implicated in
inflammasome induction and function.
Neural cell expression of inflammasome components
The above studies highlighted a role for inflamma-
some activation in RE but the cell type(s) contribut-
ing to increased inflammasome expression in the
human nervous system remain uncertain. Analyses of
mRNA from cultured primary human microglia, as-
trocytes, and neurons showed that casp1, NLRP1,
NLRP3, NLRC4, and ASC transcripts were consis-
tently detectable in human microglia (Figure 3A). In
contrast, NLRP1 transcripts were expressed at low
levels in human astrocytes, while the remaining
genes were minimally detected in astrocytes and
neurons. Thus, subsequent studies focused on pri-
mary human microglia. In order to examine expres-
sion of inflammasome components and substrates
within microglia prior to inflammasome activation,
lysates from untreated cells or cells stimulated with
TNF-α were examined by western blot. Exposure of
microglia to TNF-α induced pro-IL-1β immunoreac-
tivity in cell lysates without altering the constitutive
expression of IL-18, ASC, or caspase-1 (Figure 3B).
To explore the induction of IL-1β in more depth,
human microglia were primed with endotoxin (LPS)
as a ‘signal 1’ followed by exposure to established ac-
tivators of inflammasomes including ATP or MDP
(‘signal 2’), revealing that under these conditions LPS
alone not only induced expression of pro-IL-1β but
also triggered its cleavage, yielding the mature form
(IL-1β p17). However, this cleavage event was accen-
tuated by exposure to the signal 2 molecules (Figure 3C).
Treatment of stimulated microglia with the general cas-
pase inhibitor, zVAD-fmk, eliminated the occurrence of
mature IL-1β (Figure 3C). To investigate the release of
IL-1β from stimulated glial cells, supernatants from LPS
primed human microglia and astrocytes exposed to ATP
or MDP showed detectable IL-1β in supernatants from
microglia but without IL-1β release from astrocytes.
These studies suggested the inflammasome components
were principally located in microglia and that cultured
































































Figure 1 Neuroimaging and neuropsychological profiles in
Rasmussen’s encephalitis (RE). (A) In patient 2, coronal MRI
T2-weighted images at presentation revealed mild left hemisphere
atrophy and cortical thinning, 3 years after presentation revealing
profound left hemispheric atrophy and hyperintensity of white matter
(arrowhead), and post-hemispherectomy. Similarly, in patient 3,
increased white matter signal was evident at initial presentation but
actually resolved after corticectomy. (B) Median T scores (population
mean 50; standard deviation 10) in seven neuropsychological domains
for patients 2, 3, and 4. Median first assessments are represented
by black bars and the median last assessment as white bars.
Mann–Whitney U test, *P <0.05. MRI, magnetic resonance imaging;
RE, Rasmussen’s encephalitis.
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only a signal 1 but addition of a signal 2 enhanced the
expression and release of IL-1β.
Neuropathological studies
Given the above clinical, imaging, neuropsychological, and
molecular findings, we next examined the neuropathological
features of RE. Analyses of white matter from non-RE
and RE patients, disclosed CD3ε-immunopositive cells
were highly abundant in perivascular spaces and paren-
chyma in RE brain sections (Figure 4B) compared to
non-RE white matter (Figure 4A). CD8 immunopositive
cells were infrequently observed in the non-RE white
matter (Figure 4C) but were readily detected in RE
white matter (Figure 4D). Occasional CD68+ perivascu-
lar myeloid cells were found in the non-RE white matter
(Figure 4E), while numerous hypertrophied CD68+ cells
resembling microglia and macrophages were evident in
RE white matter including microglial nodules (Figure 4F).
Vimentin immunoreactivity was apparent in endothelial
cells in non-RE brains (Figure 4G) but was markedly in-
creased in RE white matter in both endothelia and astro-
cytes (Figure 4H). Similar neuropathological changes were
observed in the adjacent cortex from RE patients: immu-
nolabeling disclosed minimal CD3ε (Additional file 2:
Figure S2A), CD8 (Additional file 2: Figure S2B), and
CD68 (Additional file 2: Figure S1C) in non-RE cortex
compared with RE cortical sections (Additional file 2:
Figure S2D,E,F). Thus, inflammation involving activated
myeloid, lymphoid, and astrocytic cells was evident in
both white matter and cortex in RE sections.
Inflammasome expression in RE
To extend the findings of increased transcript expression
of inflammasome-associated genes in the brains from RE
patients (Figure 1), MHC class II immunoreactivity was
investigated showing markedly increased expression in
the white matter of RE brain tissues (Figure 4J) compared




































































Figure 2 Inflammatory gene expression in Rasmussen’s encephalitis (RE). A) CD3ε, HLA-DR, TNFα and GFAP mRNA median RFC of white
matter and cortical samples from RE patients (n = 3) compared to non-RE (n = 6) controls revealed significantly increased immune gene transcript
levels in RE white matter samples compared to non-RE specimens. B) IL-1β, NLRP1, NLRP3, casp1, IL-18, and C) ASC mRNA RFC of white matter and
cortical samples from RE patients compared to non-RE revealed an increase in expression of all genes in RE white matter as well as cortex
for some genes. Student’s t-test, *P >0.05. RE, Rasmussen’s encephalitis; RFC, relative fold change.
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adjacent cortex (Additional file 3: Figure S3A). IL-1β im-
munoreactivity was not detected in white matter from
non-RE patients (Figure 4K) but was apparent in RE
white matter, localized in cells resembling microglia
(Figure 4L), which was verified by co-localization
with MHC class II immunoreactivity (Figure 4L, inset).
IL-1β immunoreactivity was also detected in the
microglial-like cells in RE cortex (Additional file 3: Figure
S3B). Caspase-1 immunopositive cells, which also resem-
bled microglia, were abundant in RE white matter
(Figure 4N) in contrast to minimal detection in non-RE
tissue (Figure 4M) with similar detection levels in RE cor-
tex in microglia (Additional file 3: Figure S3D). In white
matter from RE patients, ASC immunostaining was
frequently detected in cells with morphological appear-
ance of activated myeloid cells (Figure 4P) but was
minimally found in non-RE white matter (Figure 4O).
However, ASC immunopositive cells were scarce in RE
cortex (Additional file 3: Figure S3D). These findings em-
phasized the induction of inflammasome components in
RE brain tissues, particularly in white matter, in keeping
with chronic inflammation and the associated neuroim-
aging and neuropsychological findings.
Discussion
The present study represents the first analysis of RE
patients integrating neuroimaging, neuropsychological,
neuropathological, and molecular findings, which re-
vealed both white matter and cortex involvement in the
RE disease process with a concurrent induction of
inflammasome components. This report is also one of
the first to examine inflammasome expression and acti-
vation in human neural cells (microglia, astrocytes, neu-
rons), disclosing that microglia and macrophages are
the chief cells demonstrating inflammasome cellular
machinery. There was evidence of lymphocyte invasion
of RE brain tissues, particularly CD8+ T cells, in keeping
with previous RE studies [8,22,23]. These immune pertur-
bations likely contribute to the pathogenesis of RE, perhaps
indicating an ability to respond by activating an inflam-
masome complex. The present observations also highlight










































































Figure 3 Inflammasome expression in primary human neural cells. (A) Immune gene transcript levels in primary human microglia, astrocytes,
and neurons showing that microglia express all inflammasome-associated genes examined unlike astrocytes or neurons. (B) Expression of inflamma-
some components and substrates in primary microglia ± TNF-α (50 ng/mL). (C) IL-1β expression in LPS (25 ng/mL) primed microglia co-stimulated with
ATP (500 M) or MDP (500 ng/mL) ± caspase inhibitor zVAD-fmk (100 M). (D) IL-1β release from LPS (25 ng/mL) primed microglia (but not astrocytes)
co-stimulated with ATP (500 μM) or MDP (500 ng/mL). Student’s t-test, *P <0.05.
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white matter) in RE, which was evident in multiple inves-
tigative platforms.
There has been a strong emphasis on the cerebral cortex
as the principal target of tissue damage in RE, predicated
largely on neuropathological studies showing gliosis and
neuronal dysplasia and/or loss [22,24]. However, limited
attention has been focused on pathological changes in
adjacent white matter in RE, although several earlier
studies show apparent changes in white matter in both
neuropathological and neuroimaging analyses [10,22,25].
This study integrating neuroimaging, neuropsychological as-
sessments, and expression of neuroinflammatory markers
is consistent with progressive cerebral white matter in-
volvement. The present serial neuropsychological as-
sessments reveal current (progressive) white matter





















Figure 4 Inflammatory proteins in Rasmussen’s encephalitis (RE). Immunolabeling of CD3ε revealed minimal immunoreactivity in (A) the
non-RE case and likewise (C) CD8, (E) CD68, and (G) vimentin immunoreactivity was infrequently detected in non-RE brain sections compared to
(B) marked perivascular CD3ε-positive T cell abundance, numerous (D) CD8+ T cells, (F) CD68+ macrophages, and (H) hypertrophied astrocytes
in the RE sections. Sections from the non-RE case showed negligible (I) MHC class II, (K) IL-1β, (M) caspase-1, and (O) ASC immunostaining,
while (J, L, N, P) the RE white matter exhibited robust immunoreactivity for all proteins. IL-1β immunoreactivity was evident on cells resembling
microglia in RE tissue (L, arrowheads); IL-1β (blue) was co-localized with MHC class II (brown) immunopositivity, as indicated by the arrow
(L, inset). Original magnification: panels (A,B,C,D) x100, panels (E,F,G,H,I,J,K,L,M,N,O,P) x200; size bar 10 μm, inset x600; size bar 2 μm). ACS, alanine/
serine/cysteine; MHC, major histocompatibility complex; RE, Rasmussen’s encephalitis.
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on white matter integrity; this variable worsened in the
present cohort over time. It is unclear if white matter
compromise early in the course of disease is reversible.
Importantly, the finding of impaired language function
early in the course of disease and early white matter
changes on neuroimaging might implicate either early
white matter disconnection and/or cortical injury [26].
The etiology of RE is unknown although both infectious
and autoimmune etiologies have been postulated. The
worldwide identification of RE makes an infectious agent
a less plausible etiology unless it is a ubiquitous agent
infecting a selectively ‘neurosusceptible’ group [27]. An
autoimmune pathogenesis remains a strong possibility, as
the current study revealed a combination of significant
lymphocyte infiltration and gliosis in white matter suggest-
ing immune dysregulation. Relevant to this finding, a study
of CD8+ T cells in RE reveals the persistence of cytotoxic T
lymphocytes in close proximity to neurons and astrocytes,
consistent with antigen-driven CD8+ T cells mediating at-
tack on neurons and astrocytes [8,23]. This current study
shows for the first time that inflammasome activation is
highest in human microglia and induction of the inflamma-
some results in selective release of IL-1b by microglia, but
not astrocytes. This observation, coupled with our finding
that genes involved in inflammasome activation are highest
in the white matter of RE patients, along with the ubiqui-
tous finding of microglial activation in RE supports a role
for inflammasome activation in microglia in the pathogen-
esis of RE. Currently the role of the inflammasome in other
central nervous system inflammatory disorders is unclear
particularly in other white matter diseases such as multiple
sclerosis, and warrants further investigation. Delineation of
which inflammasome complex is activated in RE might
lead to further insights into the etiopathogenesis of RE.
Both NLRP1 and NLRP3 exhibited increased expression in
RE brain specimens relative to controls with mesial tem-
poral sclerosis and multiple sclerosis (Figure 1). However, it
is plausible that other inflammasomes might exhibit in-
creased expression. Future studies will need to examine
newer inflammasome components as they become better
defined but the present studies highlight the enhanced ex-
pression of both NLRP1 and NLRP3 in brains from RE pa-
tients. Although this study is limited by small numbers due
primarily to the rarity of this disease, these findings raise
the possibility of targeting inflammasomes as part of future
therapeutic strategies for RE. Several possible agents in-
clude glyburide, which modulates pannexin-1, and new
drugs such as cytokine release inhibitory drug (CRID)3 and
milk fat globule-EGF factor 8 protein (MFGE8) [28,29].
Conclusions
The significance of white matter neuroinflammation in
terms of the etiology and pathogenesis for RE points to a
more generalized cerebral disorder. The present findings, as
well as previous studies are consistent with autoimmune or
infectious etiologies for RE. Relevant to this point, current
therapies consist of intravenous glucocorticoid therapy and
eventual hemispherectomy although tailoring treatments
to such a heterogeneous (and rare) patient population is
challenging. There is a variable response to glucocorticoids
early in RE, but eventually most patients relapse; in bilateral
hemispheric disease or late-onset dominant hemisphere
disease functional hemispherectomy is not a feasible option.
Moreover, this cohort received several broad immunosup-
pressive agents including one patient with immunoablative
cyclophosphamide treatment without discernible effects on
disease progression, suggesting that novel targeted therapies
for RE are urgently required. The findings also imply that
targeting of the inflammasomes might represent a novel
therapeutic strategy, warranting multicenter validation in
larger cohorts of patients with RE.
Additional files
Additional file 1: Figure S1. CD3ε and HLA-DRA expression in cortex
and white matter of patient 3 comparing right and left hemispheres
revealed markedly increased expression in white matter bilaterally with
minimal gene expression changes in cortex. All values were normalized
to GAPDH expression.
Additional file 2: Figure S2. Cortical changes in RE. (A) CD3ε expression
in cortex of non-RE patient compared with (B) RE. H&E staining shows
cortical injury in (D) RE cortex (i, arrow in inset) and CD8 immunoreactivity
in (B) non-RE cortex compared with (E) RE cortex. CD68 immunolabeling of
macrophages in (C) non-RE and (F) RE cortex. Original magnification: panels
(A,B,D,E) x100, panels (C,F) x200.
Additional file 3: Figure S3. Cortical changes in RE. (A) MHC class II
expression in cortex of non-RE patient compared with (E) RE. IL-1β
immunoreactivity in (B) non-RE cortex compared to (F) RE cortex.
Caspase-1 immunoreactivity in (C) non-RE cortex compared with (G) RE
cortex. ASC immunolabeling of macrophages in (D) non-RE and (H) RE
cortex. Original magnification x200.
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